|
Jun 26
|
Stocks To Watch: Biotech Leader TG Therapeutics Clears Resistance Area
|
|
Jun 21
|
Insider Sale: Director Sagar Lonial Sells 25,933 Shares of TG Therapeutics Inc (TGTX)
|
|
May 3
|
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Rainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More Optimistic
|
|
May 3
|
Why TG Therapeutics Stock Was Rocketing Higher This Week
|
|
May 2
|
TG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 2
|
TG Therapeutics Inc (TGTX) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue Growth ...
|
|
May 2
|
Q1 2024 TG Therapeutics Inc Earnings Call
|
|
May 1
|
TG Therapeutics Inc (TGTX) Surpasses Revenue Estimates in Q1 2024, Despite Widening Net Loss
|
|
May 1
|
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
Apr 30
|
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
|
|
Apr 30
|
After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics (TGTX)
|
|
Apr 18
|
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
|
|
Apr 18
|
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
|
|
Apr 15
|
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
|
|
Mar 19
|
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals?
|
|
Mar 13
|
13 Best Biotech Stocks To Buy Under $20
|
|
Mar 8
|
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
|
|
Feb 23
|
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
|
|
Feb 21
|
Institutional owners may take dramatic actions as TG Therapeutics, Inc.'s (NASDAQ:TGTX) recent 6.8% drop adds to one-year losses
|